# Vantia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vantia-therapeutics

- Industry: Biotechnology
- Headquarters: Southampton, UK
- Website: www.vantia.com
- Total disclosed funding: $63M
- Latest round: Series B (Jan 27, 2015)
- Investors on record: 3

## About

Vantia Therapeutics is a biotechnology company focused on developing innovative therapeutics for patients in need. The firm specializes in advanced drug development processes and is dedicated to addressing unmet medical needs across various therapeutic areas.Founded in 2008, Vantia Therapeutics is a biotech firm headquartered in Southampton, UK. The company focuses on the development of novel drugs and has undergone strategic pivots in its operational approach. Vantia has successfully raised a total of GBP 7.00 million in funding, most recently in a Series B round co-led by Novo Holdings A/S on March 18, 2016. The current valuation of the company is GBP 27.02 million.Vantia Therapeutics offers a range of innovative therapeutics aimed at addressing unmet medical needs. Their core offerings focus on drug development solutions for various diseases, providing advanced solutions for medical challenges. The company serves clients in healthcare sectors, primarily in North America, Europe, and Asia-Pacific, with specialized products aimed at improving patient outcomes.Vantia Therapeutics generates revenue through a model based on strategic partnerships and collaborations with pharmaceutical firms. Clients engage in long-term agreements to access Vantia's proprietary drug development services and solutions. This model fosters strong relationships and provides a stable revenue stream as the company advances its therapeutic candidates through clinical trials.Vantia Therapeutics plans to launch new therapeutics aimed at addressing specific diseases by 2024, enhancing its product portfolio. The company also intends to expand its reach into the Asian markets, particularly targeting China and Japan for growth opportunities by 2025. The recent funding round of GBP 7.00 million will support these initiatives, facilitating research and development efforts to bring new products to market.

## Funding rounds

- Series B, Jan 27, 2015, $8.9M — MVM Partners, SV Health Investors, Novo Holdings A/S
- Series B, Sep 27, 2012, $9.7M — MVM Partners, SV Health Investors, Novo Holdings A/S
- Series B, Mar 7, 2011, $6.4M — MVM Partners, SV Health Investors, Novo Holdings A/S
- Series A, Apr 13, 2010, $11M — MVM Partners
- Series A, Jan 22, 2009, $13M — MVM Partners
- Series A, Mar 6, 2008, $14M — SV Health Investors

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series A, Series B
- Novo Holdings A/S — Series B